Alpha-actinin: A multidisciplinary protein with important role in B-cell driven autoimmunity

Autoimmunity Reviews

Volumn 10, Issue 7, 2011, Pages 389-396

  Kikonomou, Katerina G ^a,b   Zachou, Kalliopi ^a,b   Dalekos, George N ^a,b  

^a INSTITUTE OF HUMAN PERFORMANCE AND REHABILITATION   (Greece)

^b UNIVERSITY OF THESSALY   (Greece)

Author keywords

Actinin; Autoimmune hepatitis; Filamentous actin; Liver autoimmunity; Lupus nephritis; Smooth muscle autoantibodies; Systemic lupus erythematosus

Indexed keywords

ALPHA ACTININ; ALPHA ACTININ 1; ALPHA ACTININ 2; ALPHA ACTININ 3; ALPHA ACTININ 4; ALPHA ACTININ ANTIBODY; ANTIBODY; CORTICOSTEROID; F ACTIN; F ACTIN ANTIBODY; IMMUNOSUPPRESSIVE AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUTROPHIL CYTOPLASMIC ANTIBODY; SINGLE STRANDED DEOXYRIBONUCLEIC ACID ANTIBODY; UNCLASSIFIED DRUG;

AUTOIMMUNE HEPATITIS; AUTOIMMUNITY; B LYMPHOCYTE; BRAIN DAMAGE; CANCER GROWTH; CELL MIGRATION; CELL MOTILITY; CELL SHAPE; CONGESTIVE CARDIOMYOPATHY; CORTICOSTEROID THERAPY; DEGENERATIVE DISEASE; EPILEPSY; FOCAL GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION; HEPATIC DUCT; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN A NEPHROPATHY; IN VIVO STUDY; METASTASIS; MYOPATHY; NEPHROTIC SYNDROME; NONHUMAN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SCHIZOPHRENIA; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; VIRUS REPLICATION;

ACTININ; ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; B-LYMPHOCYTES; HUMANS;

EID: 79955139279     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2010.12.009     Document Type: Review

References (118)

1. Maruyama K., Ebashi S. Alpha-actinin, a new structural protein from striated muscle. II. Action on actin. J Biochem 1965, 58:13-19.
2. Mimura N., Asano A. Actin-related gelation of Ehrlich tumour cell extracts is reversibly inhibited by low concentrations of Ca2+. Nature 1978, 272:273-276.
3. Sjöblom B., Salmazo A., Djinović-Carugo K. Alpha-actinin structure and regulation. Cell Mol Life Sci 2008, 65:2688-2701.
4. Otey C.A., Carpen O. Alpha-actinin revisited: a fresh look at an old player. Cell Motil Cytoskeleton 2004, 58:104-111.
5. Millake D.B., Blanchard A.D., Patel B., Critchley D.R. The cDNA sequence of a human placental α-actinin. Nucleic Acids Res 1989, 17:6725.
6. Beggs A.H., Byers T.J., Knoll J.H.M., Boyce F.M., Bruns G.A.P., Kunkel L.M. Cloning and characterization of two human skeletal muscle α-actinin genes located on chromosomes 1 and 11. J Biol Chem 1992, 267:9281-9288.
7. Honda K., Yamada T., Endo R., Ino Y., Gotoh M., Tsuda H., et al. Actinin-4, a novel actin-bundling protein associated with cell motility and cancer invasion. J Cell Biol 1998, 140:1383-1393.
8. Otey C.A., Vasquez G.B., Burridge K., Erickson B.W. Mapping of the alpha-actinin binding site within the beta 1 integrin cytoplasmic domain. J Biol Chem 1993, 268:21193-21197.
9. Rajfur Z., Roy P., Otey C., Romer L., Jacobson K. Dissecting the link between stress fibres and focal adhesions by CALI with EGFP fusion proteins. Nat Cell Biol 2002, 4:286-293.
10. Dwir O., Kansas G.S., Alon R. Cytoplasmic anchorage of L-selectin controls leucocyte capture and rolling by increasing the mechanical stability of the selectin tether. J Cell Biol 2001, 155:145-156.
11. Harazaki M., Kawai Y., Su L., Hamazaki Y., Nakahata T., Minato N., Hattori M. Specific recruitment of SPA-1 to the immunological synapse: involvement of actin-bundling protein actinin. Immunol Lett 2004, 92:221-226.
12. Mostoslavsky G., Fischel R., Yachimovich N., Yarkoni Y., Rosenmann E., Monestier M., et al. Lupus anti-DNA autoantibodies cross-react with a glomerular structural protein: a case for tissue injury by molecular mimicry. Eur J Immunol 2001, 31:1221-1227.
13. Deocharan B., Qing X., Lichauco J., Putterman C. Alpha-actinin is a cross-reactive renal target for pathogenic anti-DNA antibodies. J Immunol 2002, 168:3072-3078.
14. Mageed R.A., Zack D.J. Cross-reactivity and pathogenicity of anti-DNA autoantibodies in systemic lupus erythematosus. Lupus 2002, 11:783-786.
15. Deocharan B., Qing X., Beger E., Putterman C. Antigenic triggers and molecular targets for anti-double-stranded DNA antibodies. Lupus 2002, 11:865-871.
16. Mason L.J., Ravirajan C.T., Rahman A., Putterman C., Isenberg D.A. Is alpha-actinin a target for pathogenic anti-DNA antibodies in lupus nephritis?. Arthritis Rheum 2004, 50:866-870.
17. Zhao Z., Weinstein E., Tuzova M., Davidson A., Mundel P., Marambio P., Putterman C. Cross-reactivity of human lupus anti-DNA antibodies with alpha-actinin and nephritogenic potential. Arthritis Rheum 2005, 52:522-530.
18. Renaudineau Y., Croquefer S., Jousse S., Renaudineau E., Devauchelle V., Gueguen P., et al. Association of alpha-actinin-binding anti-double-stranded DNA antibodies with lupus nephritis. Arthritis Rheum 2006, 54:2523-2532.
19. Zhao Z., Deocharan B., Scherer P.E., Ozelius L.J., Putterman C. Differential binding of cross-reactive anti-DNA antibodies to mesangial cells: the role of alpha-actinin. J Immunol 2006, 176:7704-7714.
20. Becker-Merok A., Kalaaji M., Haugbro K., Nikolaisen C., Nilsen K., Rekvig O.P., Nossent J.C. Alpha-actinin-binding antibodies in relation to systemic lupus erythematosus and lupus nephritis. Arthritis Res Ther 2006, 8:R162.
21. Deocharan B., Zhou Z., Antar K., Siconolfi-Baez L., Angeletti R.H., Hardin J., Putterman C. Alpha-actinin immunization elicits anti-chromatin autoimmunity in nonautoimmune mice. J Immunol 2007, 179:1313-1321.
22. Renaudineau Y., Deocharan B., Jousse S., Renaudineau E., Putterman C., Youinou P. Anti-alpha-actinin antibodies: a new marker of lupus nephritis. Autoimmun Rev 2007, 6:464-468.
23. Zhang W.H., Pan H.F., Zhao X.F., Ye D.Q., Li X.P., Xu J.H. Anti-alpha-actinin antibodies in relation to new-onset systemic lupus erythematosus and lupus nephritis. Mol Biol Rep 2010, 37:1341-1345.
24. Gueguen P., Dalekos G., Nousbaum J.B., Zachou K., Putterman C., Youinou P., Renaudineau Y. Double reactivity against actin and alpha-actinin defines a severe form of autoimmune hepatitis type 1. J Clin Immunol 2006, 26:495-505.
25. Renaudineau Y., Dalekos G.N., Gueguen P., Zachou K., Youinou P. Anti-alpha actinin antibodies cross-react with anti-ssDNA antibodies in active autoimmune hepatitis. Clin Rev Allergy Immunol 2008, 34:321-325.
26. Ylanne J., Scheffzek K., Young P., Saraste M. Crystal structure of the alpha-actinin rod reveals an extensive torsional twist. Structure 2001, 9:597-604.
27. Broderick M.J.F., Winder S.J. Towards a complete atomic structure of spectrin family proteins. J Struct Biol 2002, 137:184-193.
28. Dijinovic-Carugo K., Young P., Gautel M., Saraste M. Structure of the alpha-actinin rod: molecular basis for cross-linking of actin filaments. Cell 1999, 98:537-546.
29. Franzot G., Sjoblom B., Gautel M., Djinović Carugo K. The crystal structure of the actin binding domain from alpha-actinin in its closed conformation: structural insight into phospholipid regulation of alpha-actinin. J Mol Biol 2005, 348:151-165.
30. Tang J., Taylor D.W., Taylor K.A. The three-dimensional structure of alpha-actinin obtained by cryoelectron microscopy suggests a model for Ca (2+)-dependent actin binding. J Mol Biol 2001, 310:845-858.
31. McGough A., Way M., DeRosier D. Determination of the alpha-actinin-binding site on actin filaments by cryoelectron microscopy and image analysis. J Cell Biol 1994, 126:433-443.
32. Mills M., Yang N., Weinberger R., Vander Woude D.L., Beggs A.H., Easteal S., North K. Differential expression of the actin-binding proteins, alpha-actinin-2 and -3, in different species: implications for the evolution of functional redundancy. Hum Mol Genet 2001, 10:1335-1346.
33. Luther P.K. The vertebrate muscle Z-disc: sarcomere anchor for structure and signalling. J Muscle Res Cell Motil 2009, 30:171-185.
34. North K.N., Beggs A.H. Deficiency of a skeletal muscle isoform α-actinin (α-actinin-3) in merosin-positive congenital muscular dystrophy. Neuromusc Disord 1996, 6:229-235.
35. Beggs A.H., Byers T.J., Knoll J.H., Boyce F.M., Bruns G.A., Kunkel L.M. Cloning and characterization of two human skeletal muscle α-actinin genes located on chromosomes 1 and 11. J Biol Chem 1992, 267:9281-9288.
36. Chan Y., Tong H.Q., Beggs A.H., Kunkel L.M. Human skeletal muscle-specific α-actinin-2 and -3 isoforms form homodimers and heterodimers in vitro and in vivo. Biochem Biophys Res Commun 1998, 248:134-139.
37. von Nandelstadh P., Ismail M., Gardin C., Suila H., Zara I., Belgrano A., et al. A class III PDZ binding motif in the myotilin and FATZ families binds enigma family proteins: a common link for Z-disc myopathies. Mol Cell Biol 2009, 29:822-834.
38. Pappas C.T., Bhattacharya N., Cooper J.A., Gregorio C.C. Nebulin interacts with CapZ and regulates thin filament architecture within the Z-disc. Mol Biol Cell 2008, 19:1837-1847.
39. Ilkovski B. Investigations into the pathobiology of thin-filament myopathies. Adv Exp Med Biol 2008, 642:55-65.
40. Chiu C., Bagnall R.D., Ingles J., Yeates L., Kennerson M., Donald J.A., et al. Mutations in alpha-actinin-2 cause hypertrophic cardiomyopathy: a genome-wide analysis. J Am Coll Cardiol 2010, 55:1127-1135.
41. Mohapatra B., Jimenez S., Lin J.H., Bowles K.R., Coveler K.J., Marx J.G., et al. Mutations in the muscle LIM protein and alpha-actinin-2 genes in dilated cardiomyopathy and endocardial fibroelastosis. Mol Genet Metab 2003, 80:207-215.
42. Borbely A., Toth A., Edes I., Virag L., Papp J.G., Varro A., et al. Peroxynitrite-induced alpha-actinin nitration and contractile alterations in isolated human myocardial cells. Cardiovasc Res 2005, 67:225-233.
43. North K.N., Yang N., Wattanasirichaigoon D., Mills M., Easteal S., Beggs A.H. A common nonsense mutation results in α-actinin-3 deficiency in the general population. Nat Genet 1999, 21:353-354.
44. Wyszynski M., Lin J., Rao A., Nigh E., Beggs A.H., Craig A.M., Sheng M. Competitive binding of alpha-actinin and calmodulin to the NMDA receptor. Nature 1997, 385:439-442.
45. Krupp J.J., Vissel B., Thomas C.G., Heinemann S.F., Westbrook G.L. Interactions of calmodulin and alpha-actinin with the NR1 subunit modulate Ca2+ dependent inactivation of NMDA receptors. J Neurosci 1999, 19:1165-1178.
46. Michailidis I.E., Helton T.D., Petrou V.I., Mirshahi T., Ehlers M.D., Logothetis D.E. Phosphatidylinositol-4, 5-bisphosphate regulates NMDA receptor activity through α-actinin. J Neurosci 2007, 27:5523-5532.
47. Dingledine R., Borges K., Bowie D., Traynelis S.F. The glutamate receptor ion channels. Pharmacol Rev 1999, 51:7-61.
48. Kowal C., Degiorgio L.A., Lee J.Y., Edgar M.A., Huerta P.T., Volpe B.T., et al. Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc Natl Acad Sci USA 2006, 103:19854-19859.
49. Wehland J., Osborn M., Weber K. Cell to substratum contacts in living cells. A direct correlation between interference reflection and indirect immunofluorescence microscopy using antibodies against actin and α-actinin. J Cell Sci 1979, 37:257-273.
50. Knudsen K.A., Soler A.P., Johnson K.R., Wheelock M.J. Interaction of α-actinin with the cadherin/catenin cell-cell adhesion complex via α-catenin. J Cell Biol 1995, 130:67-77.
51. Kaplan J.M., Kim S.H., North K.N., Rennke H., Correia L.A., Tong H.Q., et al. Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet 2000, 24:251-256.
52. Smoyer W.E., Mundel P., Gupta A., Welsh M.J. Podocyte α-actinin induction precedes foot process effacement in experimental nephritic syndrome. Am J Physiol 1997, 273:F150-F157.
53. Kos C.H., Le T.C., Sinha S., Henderson J.M., Kim S.H., Sugimoto H., Kalluri R., et al. Mice deficient in alpha-actinin-4 have severe glomerular disease. J Clin Invest 2003, 111:1683-1690.
54. Michaud J.L., Lemieux L.I., Dube M., Vanderhyden B.C., Robertson S.J., Kennedy C.R. Focal and segmental glomerulosclerosis in mice with podocyte-specific expression of mutant alpha-actinin-4. J Am Soc Nephrol 2003, 14:1200-1211.
55. Guan N., Ding J., Zhang J., Yang J. Expression of nephrin, podocin, alpha-actinin, and WT1 in children with nephrotic syndrome. Pediatr Nephrol 2003, 18:1122-1127.
56. Yang C., Glass W.F. Expression of α-actinin-1 in human glomelular mesangial cells in vivo and in vitro. Exp Biol Med 2008, 233:689-693.
57. Li Q., Montalbetti N., Shen P.Y., Dai X.Q., Cheeseman C.I., Karpinski G., et al. α-Actinin associates with polycystin-2 and regulates its channel activity. Hum Mol Genet 2005, 14:1587-1603.
58. Inada M., Benten D., Cheng K., Joseph B., Berishvili E., Badve S., et al. Stage-specific regulation of adhesion molecule expression segregates epithelial stem/progenitor cells in fetal and adult human livers. Hepatol Int 2008, 2:50-62.
59. Tsukada N., Ackerley C.A., Phillips M.J. The structure and organization of the bile canalicular cytoskeleton with special reference to actin and actin-binding proteins. Hepatology 1995, 21:1106-1113.
60. Beuers U. Crosstalk of liver, bile ducts and the gut. Clin Rev Allergy Immunol 2009, 36:1-3.
61. Sansonno L., Tucci F.A., Sansonno S., Lauletta G., Troiani L., Sansonno D. B cells and HCV: an infection model of autoimmunity. Autoimmun Rev 2009, 9:93-94.
62. Lan S., Wang H., Jiang H., Mao H., Liu X., Zhang X., et al. Direct interaction between alpha-actinin and hepatitis C virus NS5B. FEBS Lett 2003, 554:289-294.
63. Gluck U., Ben-Ze'ev A. Modulation of alpha-actinin levels affects cell motility and confers tumorigenicity on 3T3 cells. J Cell Sci 1994, 107:1773-1782.
64. Le Clainche C., Carlier M.-F. Regulation of actin assembly associated with protrusion and adhesion in cell migration. Physiol Rev 2008, 88:489-513.
65. Guvakova M.A., Adams J.C., Boettiger D. Functional role of alpha-actinin, PI 3-kinase and MEK1/2 in insulin-like growth factor I receptor kinase regulated motility of human breast carcinoma cells. J Cell Sci 2002, 115:4149-4165.
66. Yamamoto S., Tsuda H., Honda K., Onozato K., Takano M., Tamai S., et al. Actinin-4 gene amplification in ovarian cancer: a candidate oncogene associated with poor patient prognosis and tumor chemoresistance. Mod Pathol 2009, 22:499-507.
67. Kikuchi S., Honda K., Tsuda H., Hiraoka N., Imoto I., Kosuge T., et al. Expression and gene amplification of actinin-4 in invasive ductal carcinoma of the pancreas. Clin Cancer Res 2008, 14:5348-5356.
68. Menez J., Le Maux Chansac B., Dorothée G., Vergnon I., Jalil A., Carlier M.F., et al. Mutant alpha-actinin-4 promotes tumorigenicity and regulates cell motility of a human lung carcinoma. Ongogene 2004, 23:2630-2639.
69. Quick Q., Skalli O. Alpha-actinin 1 and alpha-actinin 4: contrasting roles in the survival, motility, and RhoA signaling of astrocytoma cells. Exp Cell Res 2010, 316:1137-1147.
70. Burridge K., Fath K., Kelly T., Nuckolls G., Turner C. Focal adhesions: transmembrane junctions between the extracellular matrix and the cytoskeleton. Annu Rev Cell Biol 1988, 4:487-525.
71. Evans S.S., Schleider D.M., Bowman L.A., Francis M.L., Kansas G.S., Black J.D. Dynamic association of L-selectin with the lymphocyte cytoskeletal matrix. J Immunol 1999, 162:3615-3624.
72. Celli L., Ryckewaert J.J., Delachanal E., Duperray A. Evidence of a functional role for interaction between ICAM-1 and nonmuscle alpha-actinins in leukocyte diapedesis. J Immunol 2006, 177:4113-4121.
73. Stanley P., Smith A., McDowall A., Nicol A., Zicha D., Hogg N. Intermediate-affinity LFA-1 binds α-actinin-1 to control migration at the leading edge of the T cell. EMBO J 2006, 27:62-75.
74. Harazaki M., Kawai Y., Su L., Hamazaki Y., Nakahata T., Minato N. Specific recruitment of SPA-1 to the immunological synapse: involvement of actin-bundling protein actinin. Immunol Lett 2004, 92:221-226.
75. Sherer Y., Gorstein A., Fritzler M.J., Shoenfeld Y. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum 2004, 34:501-537.
76. Lipsky P.E. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2001, 2:764-766.
77. Hahn B.H. Antibodies to DNA. N Engl J Med 1998, 338:1359-1368.
78. Chan O.T., Madaio M.P., Shlomchik M.J. The central and multiple roles of B-cells in lupus pathogenesis. Immunol Rev 1999, 169:107-121.
79. Migliorini P., Pratesi F., Bongiorni F., Moscato S., Scavuzzo M., Bombardieri S. The targets of nephrittogenic antibodies in systemic autoimmune disorders. Autoimmun Rev 2002, 1:168-173.
80. Shoenfeld Y. The idiotypic network in autoimmunity: antibodies that bind antibodies that bind antibodies. Nat Med 2004, 10:17-18.
81. Kalaaji M., Sturfelt G., Mjelle J.E., Nossent H., Rekvig O.P. Critical comparative analyses of anti-alpha-actinin and glomerulus-bound antibodies in human and murine lupus nephritis. Arthritis Rheum 2006, 54:914-926.
82. Manson J.J., Ma A., Rogers P., Mason L.J., Berden J.H., van der Vlag J., et al. Relationship between anti-dsDNA, anti-nucleosome and anti-alpha-actinin antibodies and markers of renal disease in patients with lupus nephritis: a prospective longitudinal study. Arthr Res Ther 2009, 11:R154.
83. Krawitt E.L. Autoimmune hepatitis. N Engl J Med 2006, 354:54-66.
84. Czaja A. Features and consequences of untreated autoimmune hepatitis. Liver Int 2009, 29:816-823.
85. Seela S., Sheela H., Boyer J.L. Autoimmune hepatitis type 1: safety and efficacy of prolonged medical therapy. Liver Int 2005, 25:734-739.
86. Dalekos G.N., Zachou K., Liaskos C., Gatselis N. Autoantibodies and defined target autoantigens in autoimmune hepatitis: an overview. Eur J Intern Med 2002, 13:293-303.
87. Zachou K., Rigopoulou E.I., Tsikrikoni A., Alexandrakis M.G., Passam F., Kyriakou D.S., Stathakis N.E., Dalekos G.N. Autoimmune hepatitis type 1 and primary biliary cirrhosis have distinct bone marrow cytokine production. J Autoimmun 2005, 25:283-288.
88. Alvarez F., Berg P.A., Bianchi F.B., Bianchi L., Burroughs A.K., Cancado E.L., et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999, 31:929-938.
89. K. Zachou, N. Gatselis, G. Papadamou, E.I. Rigopoulou, G.N. Dalekos, in press Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients. J Hepatol. [Epub ahead of print].
90. Kirk A.P., Jain S., Pocock S., et al. Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. Gut 1980, 21:78-83.
91. Hennes E., Zeniya M., Czaja A.J., Pares A., Dalekos G.N., Krawitt E.L., et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008, 48:169-176.
92. Werner M., Prytz H., Ohlsson B., Almer S., Björnsson E., Bergquist A., et al. Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study. Scand J Gastroenterol 2008, 43:1232-1240.
93. Zachou K., Rigopoulou E., Dalekos G.N. Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease. J Autoimmune Dis 2004, 1(1):2.
94. Bogdanos D.P., Dalekos G.N. Enzymes as target antigens of liver specific autoimmunity: the case of cytochromes P450s. Curr Med Chem 2008, 15:2285-2292.
95. Czaja A.J., Cassani F., Cataleta M., Valentini P., Bianchi F.B. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology 1996, 24:1068-1073.
96. Granito A., Muratori L., Muratori P., et al. Antibodies to filamentous actin (F-actin) in type 1 autoimmune hepatitis. J Clin Pathol 2006, 59:280-284.
97. Liaskos C., Bogdanos P.D., Davies E.T., Dalekos G.N. Diagnostic relevance of anti-filamentous actin antibodies in autoimmune hepatitis. J Clin Pathol 2007, 60:107-108.
98. Makaritsis K.P., Gatselis N.K., Ioannou M., Petinaki E., Dalekos G.N. Polyclonal hypergammaglobulinaemia and high smooth muscle autoantibodies titres with specificity against filamentous actin: consider visceral leishmaniasis, not only autoimmune hepatitis. Int J Infect Dis 2009, 13:e157-e160.
99. Czaja A.J., Shums Z., Norman G.L. Frequency and significance of antibodies to soluble liver antigen/liver pancreas in variant autoimmune hepatitis. Autoimmunity 2002, 35:475-483.
100. Ma Y., Okamoto M., Thomas M.G., et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 2002, 35:658-664.
101. Czaja A.J., Donaldson P.T., Lohse A.W. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 AIH. Am J Gastroenterol 2002, 97:413-419.
102. Manns M.P. Antibodies to soluble liver antigen: specific marker of autoimmune hepatitis. J Hepatol 2000, 33:326-328.
103. Baeres M., Herkel J., Czaja A.J., et al. Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut 2002, 51:259-264.
104. Gregorio G.V., Portmann B., Reid F., et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 1997, 25:541-547.
105. Czaja A.J. Autoantibodies as prognostic markers in autoimmune liver disease. Dig Dis Sci 2010, 55:2144-2161.
106. McFarlane I.G., Hegarty J.E., McSorley C.G., McFarlane B.M., Williams R. Antibodies to liver-specific protein predict outcome of treatment withdrawal in autoimmune chronic active hepatitis. Lancet 1984, 2:954-956.
107. Dejica D., Treichel U., Par A., Chira O., Meyer zum Buschenfelde K.H. Anti asialoglycoprotein receptor antibodies and soluble interleukin-2 receptor levels as marker for inflammation in autoimmune hepatitis. Z Gastroenterol 1997, 35:15-21.
108. Hausdorf G., Roggenbuck D., Feist E., et al. Autoantibodies to asialoglycoprotein receptor (ASGPR) measured by a novel ELISA-revival of a disease-activity marker in autoimmune hepatitis. Clin Chim Acta 2009, 408:19-24.
109. Jesaitis A.J., Gizachew D., Dratz E.A., Siemsen D.W., Stone K.C., Burrit J.B. Actin surface structure revealed by antibody imprints: evaluation of phage-display analysis of anti-actin antibodies. Protein Sci 1999, 8:760-770.
110. Zamanou A., Samiotaki M., Panayotou G., Margaritis L., Lymberi P. Fine specificity and subclasses of IgG anti-actin autoantibodies differ in health and disease. J Autoimmun 2003, 20:333-344.
111. McGough A., Way M., DeRosier D. Determination of the alphaactinin-binding site on actin filaments by cryoelectron microscopy and image analysis. J Cell Biol 1994, 126:433-443.
112. Zachou K., Renaudineau Y., Chauveau A., Youinou P., Dalekos G.N. Anti-alpha-actinin antibodies are independent predictors of response to treatment in autoimmune hepatitis type 1. J Hepatol 2010, 52(Suppl1):S422-S423.
113. Ichiki Y., Aoki C.A., Bowlus C.L., Shimoda S., Ishibashi H., Gershwin M.E. T cell immunity in autoimmune hepatitis. Autoimmun Rev 2005, 4:315-321.
114. Longhi M.S., Ma Y., Mieli-Vergani G., Vergani D. Aetiopathogenesis of autoimmune hepatitis. J Autoimmun 2010, 34:7-14.
115. Wies I., Brunner S., Henninger J., Herkel J., Kanzler S., Meyer zum Buschenfelde K.H., et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 2000, 355:1510-1515.
116. Costa M., Rodriguez-Sanchez J.L., Czaja A.J., Gelpi C. Isolation and characterization of cDNA encoding the antigenic protein of the human tRNP(Ser)Sec complex recognized by autoantibodies from patients with type-1 autoimmune hepatitis. Clin Exp Immunol 2000, 121:364-374.
117. Volkmann M., Martin L., Bäurle A., Heid H., Strassburg C.P., Trautwein C., et al. Soluble liver antigen: isolation of a 35kD recombinant protein (SLA-P35) specifically recognizing sera from patients with autoimmune hepatitis type 3. Hepatology 2001, 33:591-596.
118. Vidalino L., Doria A., Quarta S., Zen M., Gatta A., Pontisso P. SERPINB3, apoptosis and autoimmunity. Autoimmun Rev 2009, 9:108-112.